

Application No.: 10/027,218


Case No.: 54913US111

**Amendments to the Claims:**

The following Listing of Claims will replace all prior versions, and listings, of claims in the application:

**Listing of Claims**

1. (currently amended) A pharmaceutical composition comprising a therapeutically effective amount of a compound of the formula (I):



(I)

wherein

R<sub>1</sub> is -C<sub>2-4</sub> alkyl-NR<sub>3</sub>-CO-R<sub>4</sub> wherein R<sub>4</sub> is aryl, substituted aryl, heteroaryl, substituted heteroaryl, or alkyl;

R<sub>2</sub> is selected from the group consisting of:

- hydrogen;
- alkyl;
- alkenyl;
- aryl;
- (substituted aryl);
- heteroaryl;
- (substituted heteroaryl);
- heterocyclyl;
- (substituted heterocyclyl);
- alkyl-O-aryl;
- alkyl -O-alkyl;

Application No.: 10/027,218

Case N .: 54913US111

-alkyl-O-alkenyl; and  
-alkyl or alkenyl substituted by one or more substituents selected from the group consisting of:

- OH;
- halogen;
- N(R<sub>3</sub>)<sub>2</sub>;
- CO-N(R<sub>3</sub>)<sub>2</sub>;
- CO-C<sub>1-10</sub> alkyl;
- CO-O-C<sub>1-10</sub> alkyl;
- N<sub>3</sub>;
- aryl;
- (substituted aryl);
- heteroaryl;
- (substituted heteroaryl);
- heterocyclyl;
- (substituted heterocyclyl);
- CO-aryl; and
- CO-heteroaryl;

each R<sub>3</sub> is independently selected from the group consisting of hydrogen; C<sub>1-10</sub> alkyl-heteroaryl; C<sub>1-10</sub> alkyl-(substituted heteroaryl); C<sub>1-10</sub> alkyl-aryl; C<sub>1-10</sub> alkyl-(substituted aryl) and C<sub>1-10</sub> alkyl;

n is 0 to 4;

and each R present is independently selected from the group consisting of C<sub>1-10</sub> alkyl, C<sub>1-10</sub> alkoxy, halogen and trifluoromethyl,


wherein the substituent(s) of the substituted aryl are independently selected from the group consisting of alkyl, alkoxy, alkylthio, hydroxy, halogen, haloalkyl, haloalkylcarbonyl, haloalkoxy, nitro, alkylcarbonyl, alkenylcarbonyl, arylcarbonyl, heteroarylcarbonyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl, heterocycloalkyl, nitrile, alkoxycarbonyl,

Application No.: 10/027,218

Case No.: 54913US111

alkanoyloxy, and alkanoylthi; or a pharmaceutically acceptable salt thereof, in combination with a pharmaceutically acceptable carrier.

2. (original) The composition of claim 1 wherein  $R_3$  is hydrogen.
3. (original) The composition of claim 1 wherein  $R_2$  is selected from the group consisting of hydrogen;  $C_{1-4}$  alkyl; and  $C_{1-4}$  alkyl-O- $C_{1-4}$  alkyl.
4. (original) A pharmaceutical composition comprising a therapeutically effective amount of a compound of the formula (Ib):



(Ib)

wherein

$R_1$  is  $-C_{2-4}$  alkyl- $NR_3$ -CO- $R_4$  wherein  $R_4$  is heterocyclyl or substituted heterocyclyl;

$R_2$  is selected from the group consisting of:

- hydrogen;
- alkyl;
- alkenyl;
- aryl;
- (substituted aryl);
- heteroaryl;
- (substituted heteroaryl);

Application N .: 10/027,218

Case No.: 54913US111

-heterocyclyl;  
-(substituted heterocyclyl);  
-alkyl-O-aryl;  
-alkyl -O-alkyl;  
-alkyl-O-alkenyl; and  
-alkyl or alkenyl substituted by one or more substituents selected from the group

consisting of:

-OH;  
-halogen;  
-N(R<sub>3</sub>)<sub>2</sub>;  
-CO-N(R<sub>3</sub>)<sub>2</sub>;  
-CO-C<sub>1-10</sub> alkyl;  
-CO-O-C<sub>1-10</sub> alkyl;  
-N<sub>3</sub>;  
-aryl;  
-(substituted aryl);  
-heteroaryl;  
-(substituted heteroaryl);  
-heterocyclyl;  
-(substituted heterocyclyl);  
-CO-aryl; and  
-CO-heteroaryl;

each R<sub>3</sub> is independently selected from the group consisting of hydrogen; C<sub>1-10</sub> alkyl-heteroaryl; C<sub>1-10</sub> alkyl-(substituted heteroaryl); C<sub>1-10</sub> alkyl-aryl; C<sub>1-10</sub> alkyl-(substituted aryl) and C<sub>1-10</sub> alkyl;


n is 0 to 4;

and each R present is independently selected from the group consisting of C<sub>1-10</sub> alkyl, C<sub>1-10</sub> alkoxy, halogen and trifluoromethyl, or a pharmaceutically acceptable salt thereof, in combination with a pharmaceutically acceptable carrier.

Application No.: 10/027,218

Case No.: 54913US111

5. (original) A compound of the formula (Id):



(Id)

wherein

**R<sub>1</sub>** is -C<sub>2-4</sub> alkyl-NR<sub>3</sub>-CO-R<sub>4</sub> wherein **R<sub>4</sub>** is heteroaryl or substituted heteroaryl;

**R<sub>2</sub>** is selected from the group consisting of:

- hydrogen;
- alkyl;
- alkenyl;
- aryl;
- (substituted aryl);
- heteroaryl;
- (substituted heteroaryl);
- heterocyclyl;
- (substituted heterocyclyl);
- alkyl-O-aryl;
- alkyl -O-alkyl;
- alkyl-O-alkenyl; and
- alkyl or alkenyl substituted by one or more substituents selected from the group

consisting of:

Application No.: 10/027,218

Case No.: 54913US111

-OH;  
-halogen;  
-N(R<sub>3</sub>)<sub>2</sub>;  
-CO-N(R<sub>3</sub>)<sub>2</sub>;  
-CO-C<sub>1-10</sub> alkyl;  
-CO-O-C<sub>1-10</sub> alkyl;  
-N<sub>3</sub>;  
-aryl;  
-(substituted aryl);  
-heteroaryl;  
-(substituted heteroaryl);  
-heterocyclyl;  
-(substituted heterocyclyl);  
-CO-aryl; and  
-CO-heteroaryl;

each R<sub>3</sub> is independently selected from the group consisting of hydrogen; C<sub>1-10</sub> alkyl-heteroaryl; C<sub>1-10</sub> alkyl-(substituted heteroaryl); C<sub>1-10</sub> alkyl-aryl; C<sub>1-10</sub> alkyl-(substituted aryl) and C<sub>1-10</sub> alkyl;

n is 0 to 4;

and each R present is independently selected from the group consisting of C<sub>1-10</sub> alkyl, C<sub>1-10</sub> alkoxy, halogen and trifluoromethyl, or a pharmaceutically acceptable salt thereof.

6. (original) A compound of claim 5 wherein n is 0.


7. (original) A compound of claim 5 wherein R<sub>2</sub> is selected from the group consisting of hydrogen, C<sub>1-4</sub> alkyl, and C<sub>1-4</sub> alkyl-O-C<sub>1-4</sub> alkyl.

8. (original) A compound of claim 5 wherein R<sub>3</sub> is hydrogen.

Application N .: 10/027,218

Case N .: 54913US111

9. (original) A compound of the formula (Ie):



whercin

**R<sub>1</sub>** is -C<sub>2-4</sub> alkyl-NR<sub>3</sub>-CO-C<sub>1-8</sub> alkyl;

**R<sub>2</sub>** is selected from the group consisting of:

- hydrogen;
- alkyl;
- alkenyl;
- aryl;
- (substituted aryl);
- heteroaryl;
- (substituted heteroaryl);
- heterocyclyl;
- (substituted heterocyclyl);
- alkyl-O-aryl;
- alkyl -O-alkyl;
- alkyl-O-alkenyl; and
- alkyl or alkenyl substituted by one or more substituents selected from the group

consisting of:

- OH;
- halogen;
- N(R<sub>3</sub>)<sub>2</sub>;

Application No.: 10/027,218

Case No.: 54913US111

-CO-N(R<sub>3</sub>)<sub>2</sub>;  
-CO-C<sub>1-10</sub> alkyl;  
-N<sub>3</sub>;  
-aryl;  
-(substituted aryl);  
-heteroaryl;  
-(substituted heteroaryl);  
-heterocyclyl;  
-(substituted heterocyclyl);  
-CO-aryl; and  
-CO-heteroaryl;

each R<sub>3</sub> is independently selected from the group consisting of hydrogen; C<sub>1-10</sub> alkyl-heteroaryl; C<sub>1-10</sub> alkyl-(substituted heteroaryl); C<sub>1-10</sub> alkyl-aryl; C<sub>1-10</sub> alkyl-(substituted aryl) and C<sub>1-10</sub> alkyl;

n is 0 to 4;

and each R present is independently selected from the group consisting of C<sub>1-10</sub> alkyl, C<sub>1-10</sub> alkoxy, halogen and trifluoromethyl, or a pharmaceutically acceptable salt thereof.

10. (original) A compound of claim 9 wherein n is 0.

11. (original) A compound of claim 9 wherein R<sub>2</sub> is selected from the group consisting of hydrogen, C<sub>1-4</sub> alkyl, and C<sub>1-4</sub> alkyl-O-C<sub>1-4</sub> alkyl.

12. (original) A compound of claim 9 wherein R<sub>3</sub> is hydrogen.

13. (original) A pharmaceutical composition comprising a therapeutically effective amount of a compound selected from the group consisting of:

(2*S*,3*S*)-*N*-(4-[4-amino-2-(2-methoxyethyl)-1*H*-imidazo[4,5-*c*]quinolin-1-yl]butyl)-1-methyl-5-oxo-2-pyridin-3-ylpyrrolidine-3-carboxamide;



Application No.: 10/027,218

Case No.: 54913US111

*N*-{4-[4-amino-2-(2-methoxyethyl)-1*H*-imidazo[4,5-*c*]quinolin-1-yl]butyl}-1-[(4-*tert*-butylphenyl)sulfonyl]-*L*-prolinamide;  
*N*-[8-(4-amino-2-butyl-1*H*-imidazo[4,5-*c*]quinolin-1-yl)octyl]benzamide;  
*N*-{8-[4-amino-2-(2-methoxyethyl)-1*H*-imidazo[4,5-*c*]quinolin-1-yl]octyl}benzamide;  
*N*-[3-(4-amino-2-butyl-1*H*-imidazo[4,5-*c*]quinolin-1-yl)propyl]benzamide;  
*N*-{3-[4-amino-2-(2-methoxyethyl)-1*H*-imidazo[4,5-*c*]quinolin-1-yl]-2,2-dimethylpropyl}benzamide;  
*N*-[8-(4-amino-1*H*-imidazo[4,5-*c*]quinolin-1-yl)octyl]benzamide;  
*N*-{3-[4-amino-2-(3-phenoxypropyl)-1*H*-imidazo[4,5-*c*]quinolin-1-yl]propyl}-4-bromobenzamide;  
*N*-{3-[4-amino-2-(3-phenoxypropyl)-1*H*-imidazo[4,5-*c*]quinolin-1-yl]propyl}benzamide;  
*N*-{3-[4-amino-2-(2-methoxyethyl)-6,7,8,9-tetrahydro-1*H*-imidazo[4,5-*c*]quinolin-1-yl]propyl}benzamide; and  
*N*-{3-[4-amino-2-(2-methoxyethyl)-1*H*-imidazo[4,5-*c*]quinolin-1-yl]propyl}benzamide; or a pharmaceutically acceptable salt thereof in combination with a pharmaceutically acceptable carrier.

14. (original) A compound selected from the group consisting of:

*N*-{4-[4-amino-2-(2-methoxyethyl)-1*H*-imidazo[4,5-*c*]quinolin-1-yl]butyl}isoquinoline-3-carboxamide;  
*N*-{4-[4-amino-2-(2-methoxyethyl)-1*H*-imidazo[4,5-*c*]quinolin-1-yl]butyl}quinoline-3-carboxamide;  
*N*-{4-[4-amino-2-(2-methoxyethyl)-1*H*-imidazo[4,5-*c*]quinolin-1-yl]butyl}quinoxaline-2-carboxamide;  
*N*-[3-(4-amino-2-butyl-1*H*-imidazo[4,5-*c*]quinolin-1-yl)propyl]isoquinoline-3-carboxamide;  
*N*-{3-[4-amino-2-(2-methoxyethyl)-1*H*-imidazo[4,5-*c*]quinolin-1-yl]propyl}isoquinoline-3-carboxamide;  
*N*-[4-(4-amino-2-ethyl-1*H*-imidazo[4,5-*c*]quinolin-1-yl)butyl]cyclopentanecarboxamide;  
*N*-[4-(4-amino-2-methyl-1*H*-imidazo[4,5-*c*]quinolin-1-yl)butyl]cyclohexanecarboxamide;  
*N*-[4-(4-amino-2-ethyl-1*H*-imidazo[4,5-*c*]quinolin-1-yl)butyl]-2-methylpropanamide;

Application No.: 10/027,218

Case N .: 54913US111

*N*-[4-(4-amino-2-ethyl-1*H*-imidazo[4,5-*c*]quinolin-1-yl)butyl]butanamide;  
*N*-[4-(4-amino-2-methyl-1*H*-imidazo[4,5-*c*]quinolin-1-yl)butyl]cyclopentanecarboxamide;  
*N*-[4-(4-amino-2-methyl-1*H*-imidazo[4,5-*c*]quinolin-1-yl)butyl]-2-methylpropanamide;  
*N*-[4-(4-amino-2-methyl-1*H*-imidazo[4,5-*c*]quinolin-1-yl)butyl]butanamide;  
*N*-[4-(4-amino-2-ethyl-1*H*-imidazo[4,5-*c*]quinolin-1-yl)butyl]cyclohexanecarboxamide;  
*N*-[3-(4-amino-2-methyl-1*H*-imidazo[4,5-*c*]quinolin-1-yl)propyl]cyclohexanecarboxamide;  
*N*-[3-(4-amino-2-methyl-1*H*-imidazo[4,5-*c*]quinolin-1-yl)propyl]cyclopentanecarboxamide;  
*N*-[3-(4-amino-2-methyl-1*H*-imidazo[4,5-*c*]quinolin-1-yl)propyl]-2-methylpropanamide;  
*N*-[3-(4-amino-2-methyl-1*H*-imidazo[4,5-*c*]quinolin-1-yl)propyl]butanamide; and  
*N*-{2-[4-amino-2-(ethoxymethyl)-1*H*-imidazo[4,5-*c*]quinolin-1-yl]-1,1-dimethylethyl}-2-ethoxyacetamide;  
or a pharmaceutically acceptable salt thereof.

15. (original) A pharmaceutical composition comprising a therapeutically effective amount of a compound of claim 5 in combination with a pharmaceutically acceptable carrier.

16. (original) A pharmaceutical composition comprising a therapeutically effective amount of a compound of claim 9 in combination with a pharmaceutically acceptable carrier.

17 (original) A pharmaceutical composition comprising a therapeutically effective amount of a compound of claim 14 in combination with a pharmaceutically acceptable carrier.

18. (currently amended) A method of inducing cytokine biosynthesis in an animal comprising administering an effective amount of a composition of claim 1 to the animal, wherein the cytokine is interferon- $\alpha$  or tumor necrosis factor- $\alpha$ .

19. (currently amended) A method of inducing cytokine biosynthesis in an animal comprising administering an effective amount of a composition of claim 4 to the animal, wherein the cytokine is interferon- $\alpha$  or tumor necrosis factor- $\alpha$ .

Application N .: 10/027,218

Case No.: 54913US111

---

20. (currently amended) A method of inducing cytokine biosynthesis in an animal comprising administering an effective amount of a composition of claim 13 to the animal, wherein the cytokine is interferon- $\alpha$  or tumor necrosis factor- $\alpha$ .

21. (currently amended) A method of inducing cytokine biosynthesis in an animal comprising administering an effective amount of a composition of claim 15 to the animal, wherein the cytokine is interferon- $\alpha$  or tumor necrosis factor- $\alpha$ .

22. (currently amended) A method of inducing cytokine biosynthesis in an animal comprising administering an effective amount of a composition of claim 16 to the animal, wherein the cytokine is interferon- $\alpha$  or tumor necrosis factor- $\alpha$ .

23. (currently amended) A method of inducing cytokine biosynthesis in an animal comprising administering an effective amount of a composition of claim 17 to the animal, wherein the cytokine is interferon- $\alpha$  or tumor necrosis factor- $\alpha$ .